The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis

被引：5

作者：

Garg, Anubhav ^{[1
]}

Nanji, Keean ^{[1
,2
]}

Tai, Felicia ^{[1
]}

Phillips, Mark ^{[2
]}

Zeraatkar, Dena ^{[2
]}

Garg, Sunir J. ^{[3
]}

Sadda, SriniVas R. ^{[4
,5
]}

Kaiser, Peter K. ^{[6
]}

Guymer, Robyn H. ^{[7
,8
]}

Sivaprasad, Sobha ^{[9
,10
]}

Wykoff, Charles C. ^{[11
,12
]}

Chaudhary, Varun ^{[1
,2
]}

机构：

[1] McMaster Univ, Dept Surg, Div Ophthalmol, Hamilton, ON, Canada

[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada

[3] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, Philadelphia, PA USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA

[5] Doheny Eye Inst, Los Angeles, CA USA

[6] Cleveland Clin, Cole Eye Inst, Cleveland, OH USA

[7] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia

[8] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia

[9] UCL, Inst Ophthalmol, London, England

[10] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England

[11] Retina Consultants Texas, Houston, TX USA

[12] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX USA

来源：

SURVEY OF OPHTHALMOLOGY | 2024年 / 69卷 / 03期

关键词：

Age-related macular degeneration; Avacincaptad pegol; C3; C5; Complement; Eculizumab; Geographic atrophy; Living systematic review; Meta-analysis; Pegcetacoplan; PREVALENCE; DISEASE;

D O I：

10.1016/j.survophthal.2023.11.008

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

With the introduction of therapies to treat geographic atrophy (GA), GA management in clinical practice is now possible. A living systematic review can provide access to timely and robust evidence synthesis. This review found that complement factor 3 and 5 (C3 and C5) inhibition compared to sham likely reduces change in square root GA area at 12 months and untransformed GA area at 24 months. There is likely little to no difference in the rate of systemic treatment-emergent adverse events compared to sham. C3 and C5 inhibition, however, likely does not improve best-corrected visual acuity (BCVA) at 12 months, and the evidence is uncertain regarding change in BCVA at 24 months. Higher rates of ocular treatment emergent adverse effects with complement inhibition occur at 12 months and likely at 24 months. Complement inhibition likely results in new onset neovascular age-related macular degeneration at 12 months. This living meta-analysis will continuously incorporate new evidence.

引用

页码：349 / 361

页数：13

共 49 条

[1] A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol [J].

Beck, RW ;

Moke, PS ;

Turpin, AH ;

Ferris, FL ;

Sangiovanni, JP ;

Johnson, CA ;

Birch, EE ;

Chandler, DL ;

Cox, TA ;

Blair, RC ;

Kraker, RT .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (02) :194-205

[2]

Bogunovic H, 2021, INVEST OPHTH VIS SCI, V62

[3]

ClinicalTrials.gov, 2019, 2000 Feb 29 -. Identifier NCT02247479, A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

[4]

ClinicalTrials.gov, A study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration

[5]

ClinicalTrials.gov, 2023, Identifier NCT03815825, GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

[6]

ClinicalTrials.gov, 2022, Identifier NCT05536297, Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

[7]

ClinicalTrials.gov, 2021, Identifier NCT04770545, An Extension Study to Evaluate the Long- term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

[8]

Danzig C, 2023, ASS RES VIS OPHTH 20

[9] Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration [J].

de Amorim Garcia Filho, Carlos Alexandre ;

Yehoshua, Zohar ;

Gregori, Giovanni ;

Nunes, Renata Portella ;

Penha, Fernando M. ;

Moshfeghi, Andrew A. ;

Zhang, Kang ;

Feuer, William ;

Rosenfeld, Philip J. .

OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2014, 45 (01) :18-31

[10]

Deeks JJ, 2022, Cochrane Training

← 1 2 3 4 5 →